Rhythm Pharmaceuticals reports positive Phase 2 results for bivamelagon in acquired hypothalamic obesity, plans Phase 3 by end of 2026

Rhythm Pharmaceuticals announced positive Phase 2 clinical trial results for its therapeutic candidate bivamelagon in treating acquired hypothalamic obesity. The company plans to initiate a pivotal Phase 3 trial by end of 2026, with first patient dosing anticipated in January 2027.

Detected & updated continuously · Source: Nebula